"Anti-Bacterial Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit the growth or reproduction of BACTERIA.
| Descriptor ID |
D000900
|
| MeSH Number(s) |
D27.505.954.122.085
|
| Concept/Terms |
Anti-Bacterial Agents- Anti-Bacterial Agents
- Agents, Anti-Bacterial
- Anti Bacterial Agents
- Antibacterial Agents
- Agents, Antibacterial
- Anti-Bacterial Compounds
- Anti Bacterial Compounds
- Compounds, Anti-Bacterial
Anti-Mycobacterial Agents- Anti-Mycobacterial Agents
- Agents, Anti-Mycobacterial
- Anti Mycobacterial Agents
- Antimycobacterial Agents
- Agents, Antimycobacterial
|
Below are MeSH descriptors whose meaning is more general than "Anti-Bacterial Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Bacterial Agents".
This graph shows the total number of publications written about "Anti-Bacterial Agents" by people in this website by year, and whether "Anti-Bacterial Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 13 | 8 | 21 |
| 1997 | 16 | 6 | 22 |
| 1998 | 7 | 11 | 18 |
| 1999 | 9 | 8 | 17 |
| 2000 | 15 | 9 | 24 |
| 2001 | 11 | 9 | 20 |
| 2002 | 19 | 10 | 29 |
| 2003 | 19 | 13 | 32 |
| 2004 | 11 | 11 | 22 |
| 2005 | 18 | 14 | 32 |
| 2006 | 30 | 15 | 45 |
| 2007 | 19 | 24 | 43 |
| 2008 | 26 | 18 | 44 |
| 2009 | 29 | 24 | 53 |
| 2010 | 38 | 24 | 62 |
| 2011 | 40 | 18 | 58 |
| 2012 | 34 | 23 | 57 |
| 2013 | 36 | 29 | 65 |
| 2014 | 47 | 19 | 66 |
| 2015 | 41 | 33 | 74 |
| 2016 | 43 | 24 | 67 |
| 2017 | 59 | 31 | 90 |
| 2018 | 49 | 51 | 100 |
| 2019 | 52 | 50 | 102 |
| 2020 | 42 | 61 | 103 |
| 2021 | 35 | 66 | 101 |
| 2022 | 18 | 66 | 84 |
| 2023 | 11 | 75 | 86 |
| 2024 | 53 | 32 | 85 |
| 2025 | 52 | 36 | 88 |
| 2026 | 34 | 15 | 49 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Bacterial Agents" by people in Profiles.
-
Mechanistic Roles of Conserved Active-Site Residues in OXA-48 Carbapenem Hydrolysis. ACS Infect Dis. 2026 Sep 11; 12(9):3241-3252.
-
Comparative adjuvant therapy to reduce vancomycin-associated nephrotoxicity in an animal model. Antimicrob Agents Chemother. 2026 Oct 07; 70(10):e0088726.
-
A comparative analysis of performance and time-to-result for VITEK REVEAL versus MicroScan during antimicrobial susceptibility testing for gram-negative bacteremia. Microbiol Spectr. 2026 Oct 06; 14(10):e0162626.
-
In vitro activity of beta-lactam/beta-lactamase inhibitors, colistin, tigecycline, and eravacycline against carbapenemase-producing uropathogenic Enterobacterales. Future Microbiol. 2026 Aug; 21(12):1147-1157.
-
Clinical Practice Guidelines by Infectious Diseases Society of America (IDSA): 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections--Duration of Antibiotics for Complicated UTI. Clin Infect Dis. 2026 08 24; 82(Suppl 3):i79-i88.
-
Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections - Timing of Intravenous to Oral Antibiotics Transition for Complicated Urinary Tract Infections. Clin Infect Dis. 2026 08 24; 82(Suppl 3):i68-i78.
-
Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections-Selection of Antibiotic Therapy for Complicated Urinary Tract Infections. Clin Infect Dis. 2026 08 24; 82(Suppl 3):i36-i67.
-
Development and validation of a novel LC-MS/MS method for simultaneous quantification of fidaxomicin and metabolite (OP-1118) from feces for gut pharmacobiome studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2026 Oct 01; 1282:125249.
-
Microbiome Stewardship: re-defining high-risk antibiotics. Anaerobe. 2026 Sep; 99:103072.
-
Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains. Antimicrob Agents Chemother. 2026 09 02; 70(9):e0048226.